FDA staff highlight heart risk with Novo insulin

159749384

Novo Nordisk’s new ultra long-acting insulin degludec is associated with a higher heart risk than other diabetes treatments, although the size of the risk is uncertain, U.S. regulators said on Tuesday.

Read more

Posted in Glucose & Insulin